ViewRay Inc
$
7.02
0 (0%)
| Volume: | 774,242 | Avg Vol (1m): | 1,239,714 |
| Market Cap $: | 678.62 Mil | Enterprise Value $: | 566.55 Mil |
| P/E (TTM): | 0.00 | P/B: | 4.02 |
| Earnings Power Value | -27.14 |
| Net Current Asset Value | 1.56 |
| Tangible Book | 1.74 |
| Projected FCF | 0 |
| Median P/S Value | 9.4 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 3.02 | ||
| Equity-to-Asset | 0.57 | ||
| Debt-to-Equity | 0.33 | ||
| Debt-to-EBITDA | -0.85 | ||
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.71 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 0.05 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -359.19%
WACC 16.19%
| ||
Profitability & Growth : 3/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -92.75 | ||
| Net Margin % | -94.36 | ||
| ROE % | -89.45 | ||
| ROA % | -36.20 | ||
| ROC (Joel Greenblatt) % | -145.23 | ||
| 3-Year Total Revenue Growth Rate | 98.30 | ||
| 3-Year Total EBITDA Growth Rate | -17.40 | ||
| 3-Year EPS w/o NRI Growth Rate | 27.60 |
» VRAY's 30-Y Financials
Financials (Next Earnings Date: 2019-05-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:VRAY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Devices » Medical Devices   NAICS : 334510   SIC : 3842 |
| Compare | XKRX:043150 NAS:ARAY HKSE:01789 SZSE:300314 SZSE:300562 NAS:TCMD XKRX:085370 NYSE:IVC XKRX:099190 NAS:NMRD HKSE:01696 OSTO:HANDI XKRX:060280 ROCO:8406 XBRU:IBAB NAS:GNMK AMEX:CVRS HKSE:03600 SZSE:300206 NAS:RTIX |
| Traded in other countries | 6L9.Germany |
| Address | 2 Thermo Fisher Way, Oakwood Village, OH, USA, 44146 |
| ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures and markets radiation therapy systems which provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRLdian system, Monte Carlo treatment planning system etc. The company holds license for its combination of MRi and radiation therapy technologies. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 4.02 | ||
| PS Ratio | 6.87 | ||
| EV-to-EBIT | -8.23 | ||
| EV-to-EBITDA | -8.69 | ||
| EV-to-Revenue | 6.99 | ||
| Current Ratio | 5.15 | ||
| Quick Ratio | 4.24 | ||
| Days Inventory | 165.32 | ||
| Days Sales Outstanding | 166.21 | ||
| Days Payable | 67.90 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -28.50 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.03 | ||
| Price-to-Median-PS-Value | 0.75 | ||
| Earnings Yield (Joel Greenblatt) % | -12.12 |
More Statistics
| Revenue (TTM) (Mil) $ | 80.96 |
| EPS (TTM) $ | -0.97 |
| Beta | 2.28 |
| Volatility % | 87.89 |
| 52-Week Range $ | 4.86 - 13.21 |
| Shares Outstanding (Mil) | 96.67 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |